Table 1. Most significant categories and functions.
| DISEASE AND DISORDERS | p-value |
| Immunological disease | 3.11E-04 -2.13E-02 |
| Neurological disease | 3.11E-04 -2.30E-02 |
| Skeletal and Muscular Disorders | 3.11E-04 -1.77E-02 |
| Cancer | 9.22E-04 -2.46E-02 |
| Reproductive System Disease | 9.22E-04 -1.77E-02 |
| MOLECULAR AND CELLULAR FUNCTIONS | p-value |
| Cell Death and Survival | 1.05E-04 -2.13E-02 |
| Cellular Development | 1.81E-04 -1.83E-02 |
| Cell Morphology | 2.85E-04 -1.77E-02 |
| Cellular Movement | 5.95E-04 -2.46E-02 |
| Cell-To-Cell Signaling and Interaction | 1.25E-03 -2.46E-02 |
| PATHWAYS | -log(p-value) |
| Lanosterol Biosynthesis | 1.75E00 |
| Netrin Signaling | 1.73E00 |
| Epithelial Adherens Junction Signaling | 1.62E00 |
| Fatty Acid Biosynthesis Initiation II | 1.46E00 |
| Palmitate Biosynthesis I (Animals) | 1.46E00 |
| Urea Cycle | 1.46E00 |
| Calcium Signaling | 1.42E00 |
| TOP CARDIOTOXIC FUNCTIONS | p-value |
| Increased Levels of Albumin | 1.77E-02 -1.77E-02 |
| Increased Levels of Alkaline Phosphatase | 1.77E-02 -6.12E-01 |
| Cardiac Arrythmia | 4.07E-03 -3.25E-01 |
| Tachycardia | 4.07E-03 -3.25E-01 |
| Cardiac Dilation | 1.77E-02 -1.45E-01 |
| Congenital Heart Anomaly | 1.77E-02 -4.35E-01 |
| Cardiac Hypoplasia | 3.95E-02 -3.95E-02 |